Introduction
In the last three decades, the prevalence of coronary artery disease (CAD) has increased from 1.1% to about 7.5% in the urban population and from 2.1% to 3.7% in the rural population. 1 Coronary artery disease tends to occur at a younger age in Indians with 50% of cardiovascular (CV) mortality occurring in individuals aged less than 50 years. 2, 3 In a view of high prevalence of CAD in India there is a need for cardiologists' even physicians' to be updated on the recent developments in diagnosis and treatment. However, currently every clinician is inundated with numerous data (for which he/she may have not have sufficient time to go through). Herein clinical guidelines provide a quick solution for day-to-day problems and assist physicians, particularly cardiologists, in clinical decisionmaking by delineating a gamut of commonly acceptable modalities for the diagnosis, management, and prevention of stable CAD (SCAD). On the other hand guidelines by themselves may have several limitations; they are generally developed based on practice in West (which might be different in developing world), they are too many, and they may be difficult to understand by an average physician. In this context practice standards and management algorithms may offer better guidance to a practicing physician.
The current practice standard has defined practices that meet the needs of most patients in the Indian context. A modified GRADE system was used to derive quality of evidence as 1 (high-quality evidence from consistent results of well-performed randomised trials), 2 (moderate quality evidence from randomised trials), 3 (low-quality evidence from observational studies), or 4 (practice point). The strength of recommendations was categorised as either A (''RECOMMENDED'', strong recommendation) or B (''SUG-GESTED'', weak recommendation).
Diagnosis
Patient's history and physical examination should be considered to identify all the symptoms and signs of CV disease, CV risk factors, and other cardiac aetiologies. (Grade A, Evidence level 3) 4, 5 The basic first-line testing in patients with suspected SCAD includes standard laboratory biochemical testing (including haemoglobin, glycated haemoglobin [HbA1c], lipid profile, liver, renal and thyroid function tests), a resting ECG, resting echocardiography and, a chest X-ray. (Grade A, Evidence level 3) [6] [7] [8] [9] [10] [11] It is recommended to include assessment of resting heart rate in SCAD patients as a routine clinical practice. ( All the SCAD patients should be treated with statins to achieve optimal LDL-C goal <70 mg/dl. [Grade A, Evidence 2] The addition of long-acting nitrates or trimetazidine or ivabradine or ranolazine or nicorandil is proposed in case of intolerance or contraindications or failure in achieving angina control by b-blockers and/or calcium channel blockers. The choice of the drug should be made on the basis of blood pressure, heart rate and tolerance. (Grade A, Evidence level 2) [47] [48] [49] [50] [51] [52] [53] [54] Ivabradine may be considered in symptomatic patients who do not tolerate beta-blockers or in whom the resting heart rate remains above 70 bpm, despite administration of the full tolerable dose of beta-blockers. [Grade: A, Evidence: 2] 51, 55, 56 When two haemodynamically acting drugs fail to achieve the desired results in reducing angina, preference may be given to cardio-metabolic agents like trimetazidine or ranolazine which has a different mode of action and offers better efficacy in combination with a haemodynamic agent. (Grade A, Evidence level 2) 57, 58 5. Event prevention (Fig. 2) Indefinite daily low-dose aspirin is recommended in all SCAD patients if not contraindicated. (Grade A, Evidence level 1) [59] [60] [61] Clopidogrel is recommended in patients with aspirin intolerance. (Grade A, Evidence level 2) [62] [63] [64] [65] In view of absence of any trial showing the benefit of prasugrel or ticagrelor in stable angina patients and also considering their cost in this sub-set of patients, they may be avoided pending results of the trials addressing this issue. [Grade A, Evidence 4] Statin should be prescribed in all patients with SCAD irrespective of lipid levels. (Grade A, Evidence level 2) 66 All stable angina patients with diabetes, hypertension, heart failure or early chronic kidney disease should be recommended to receive angiotensin converting enzyme (ACE) inhibitors if not contra-indicated. (Grade A, Evidence level 1) [67] [68] [69] [70] Rest of the patients with SCAD should also be recommended to receive ACE inhibitors. (Grade A, Evidence level 2) [69] [70] [71] A combination of ACE inhibitors and amlodipine may be considered in hypertensive CAD patients for improving CV outcomes. (Grade A, Evidence level 2) [72] [73] [74] Angiotensin receptor blockers treatment may be used as an alternative therapy for patients who are intolerant to ACE inhibitors. (Grade A In patients who continue to be symptomatic agents like trimetazidine, nicorandil, ranolazine and ivabradine may be effective. [Grade A, Evidence 3]
Revascularisation
The decision of considering revascularisation in patient with SCAD should be individualised. Revascularisation can be opted early when patients symptoms are uncontrolled by medical therapy alone and/or have high-risk features. (Grade A, Evidence level 4) 6 While selecting whether PCI or CABG for revascularisation, the decision should be purely individualised and consensus based. (Grade A, Evidence level 4) 6 The management algorithm of stable coronary artery disease is given in Fig. 1A & B. Abbreviations: SCAD, stable coronary artery disease; CT, computed tomographic; ECG, electrocardiogran1; LAD, left anterior descending; TVD, triple vessel disease; LV, left ventricular; SVD, single vessel disease; DVD, double vessel disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; EF, ejection fraction; ASA, acetyl salicylic acid (aspirin); ACEls, angiotensin-converting-enzyme inhibitors; ARB, angiotensin receptor blocker; BBs, beta-blockers; CCBs, calcium channel blockers; DHP, Dihydropyridine; HR, heart rate; BP, blood pressure.
The management algorithm of silent myocardial ischaemia, microvascular angina and vasospastic angina is given in Fig. 2A , B & C, respectively.
Treatment of special groups of population

Diabetes
An objective for HbA 1c of <7.0% and blood pressure <140/ 85 mmHg is recommended for the prevention of microvascular disease in diabetic patients. (Grade A, Evidence level 2) 31,32, 37, 38 All SCAD patients with diabetes should be recommended to receive an aspirin, high intensity statin and ACE inhibitor or a combination of ACE inhibitor with diuretic if not contraindicated. 
Chronic kidney disease
All stable angina patients with chronic kidney disease should be recommended to receive optimal medical therapy. ACE inhibitors can be used if not contra-indicated with careful monitoring of serum creatinine and potassium levels. (Grade A, Evidence level 4) 36 
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